Traws Pharma (FRA:0T20) Cyclically Adjusted FCF per Share: €-13,139.37 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:0T20 Traws Pharma Inc FRA:0T20
40 GF Score
Price €6.60
GF Value €178.12
! 4 Warning Signs
View Full Analysis

What is Traws Pharma Cyclically Adjusted FCF per Share?

Traws Pharma FRA:0T20 40 Cyclically Adjusted FCF per Share is €-13,139.37 as of Mar. 2026. GuruFocus rates FRA:0T20 with a GF Score™ of 40/100 and a GF Value™ of €178.12. The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Traws Pharma's adjusted free cash flow per share for the three months ended in Mar. 2026 was €-0.209. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-13,139.37 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 9.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Traws Pharma was 9.80% per year. The lowest was 9.20% per year. And the median was 9.50% per year.

As of today (2026-07-31), Traws Pharma's current stock price is €6.60. Traws Pharma's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €-13,139.37. Traws Pharma's Cyclically Adjusted Price-to-FCF of today is .


Traws Pharma  (FRA:0T20) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Traws Pharma Cyclically Adjusted FCF per Share Related Terms


Traws Pharma Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Traws Pharma's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Traws Pharma Cyclically Adjusted FCF per Share Chart

Traws Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4,608.86 -4,538.03 -3,831.97 -2,968.34 -21,431.31

Traws Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11,281.12 -17,192.20 -13,475.10 -21,431.31 -13,139.37

FRA:0T20 vs CNSP, MTVA, LIMN: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Traws Pharma's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Traws Pharma Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Traws Pharma's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Traws Pharma's Cyclically Adjusted Price-to-FCF falls into.


FRA:0T20
40GF Score
Traws Pharma Inc FRA:0T20
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Traws Pharma Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Traws Pharma's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.209/330.2130*330.2130
=-0.209

Current CPI (Mar. 2026) = 330.2130.

Traws Pharma Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 0.000 241.018 0.000
201609 -2,545.000 241.428 -3,480.922
201612 -4,136.000 241.432 -5,656.918
201703 -5,662.000 243.801 -7,668.820
201706 -2,533.500 244.955 -3,415.299
201709 -3,103.500 246.819 -4,152.095
201712 -1,974.500 246.524 -2,644.796
201803 -1,489.333 249.554 -1,970.704
201806 -359.818 251.989 -471.515
201809 -408.733 252.439 -534.660
201812 -317.000 251.233 -416.655
201903 -365.125 254.202 -474.304
201906 -271.500 256.143 -350.011
201909 -224.813 256.759 -289.128
201912 -16.297 256.974 -20.942
202003 -13.666 258.115 -17.483
202006 -10.571 257.797 -13.540
202009 -10.151 260.280 -12.878
202012 -9.099 260.474 -11.535
202103 -9.545 264.877 -11.899
202106 -5.666 271.696 -6.886
202109 -5.676 274.310 -6.833
202112 -4.505 278.802 -5.336
202203 -4.666 287.504 -5.359
202206 -4.768 296.311 -5.314
202209 -4.706 296.808 -5.236
202212 -4.380 296.797 -4.873
202303 -5.063 301.836 -5.539
202306 -4.939 305.109 -5.345
202309 -4.985 307.789 -5.348
202312 -4.836 306.746 -5.206
202403 -4.834 312.332 -5.111
202406 -9.044 314.175 -9.506
202409 -10.748 315.301 -11.256
202412 -1.057 315.605 -1.106
202503 -0.697 319.799 -0.720
202506 -0.891 322.561 -0.912
202509 -0.387 324.800 -0.393
202512 -0.248 324.054 -0.253
202603 -0.209 330.213 -0.209

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-13,139.37 mean?
Traws Pharma (FRA:0T20) has a Cyclically Adjusted FCF per Share of €-13,139.37 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Traws Pharma and its competitors.
Is Traws Pharma's Cyclically Adjusted FCF per Share too high?
Traws Pharma's current Cyclically Adjusted FCF per Share is €-13,139.37. Overall, Traws Pharma has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does Traws Pharma's Cyclically Adjusted FCF per Share compare to CNSP and MTVA?
Traws Pharma's Cyclically Adjusted FCF per Share of €-13,139.37 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Traws Pharma and its competitors. Traws Pharma's current Cyclically Adjusted FCF per Share is €-13,139.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Traws Pharma stock overvalued right now?
Traws Pharma (FRA:0T20) has a current Cyclically Adjusted FCF per Share of €-13,139.37. The stock's GF Value™ is €178.12, compared to a current price of €6.60 — trading 96.3% below its estimated fair value. The current Cyclically Adjusted FCF per Share is €-13,139.37. Traws Pharma's overall GF Score™ is 40/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Traws Pharma (FRA:0T20), the current Cyclically Adjusted FCF per Share is €-13,139.37 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Traws Pharma (FRA:0T20) Overvalued in 2026?

Based on GuruFocus' analysis, Traws Pharma stock appears to be undervalued. The current stock price of €6.60 is trading 96.3% below its estimated GF Value™ of €178.12.

Key valuation signals for FRA:0T20:

  • Cyclically Adjusted FCF per Share: €-13,139.37
  • GF Value™: €178.12 vs. price of €6.60 (96.3% below fair value)
  • GF Score™: 40/100 with 4 warning signs

No single metric tells the full story. See the FRA:0T20 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Traws Pharma Business Description

Other Exchanges TRAW:USA
Address 12 Penns Trail, Newtown, PA, USA, 18940
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib. The company has four clinical programs: (i) tivoxavir marboxil, (ii) ratutrelvir, (iii) narazaciclib (ON 123300), and (iv) rigosertib. It is focused on the development of tivoxavir marboxil and ratutrelvir. The company derives revenue from its collaboration and licensing agreements.
40GF Score

Get the complete analysis for FRA:0T20

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.60
Price
€178.12
GF Value